Evidence map›Paper›PMID 42548570›Full record

ArticleCHEST pulmonary2025

Health State Utilities Associated With Treatment Burden in Cystic Fibrosis: A Patient Valuation Study.

Rory A Cameron, Jessie Matthews, Daniel Office, Mark Rowley, Janice Abbott, Nicholas J Simmonds, Jennifer A Whitty, Siobhán B Carr

Abstract read
In one paragraph

Article in CHEST pulmonary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rory A CameronNorwich Medical School, University of East Anglia, Norwich, England.
Jessie MatthewsAdult Cystic Fibrosis Centre, Royal Brompton Hospital, London, England.
Daniel OfficeAdult Cystic Fibrosis Centre, Royal Brompton Hospital, London, England.
Mark Rowleypatient representative, London, England.
Janice AbbottSchool of Psychology, University of Central Lancashire, Preston, England.
Nicholas J SimmondsAdult Cystic Fibrosis Centre, Royal Brompton Hospital, London, England.
Jennifer A WhittyNorwich Medical School, University of East Anglia, Norwich, England.
Siobhán B CarrNational Heart and Lung Institute, Imperial College, London, England.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although recent advancements in the treatment of cystic fibrosis (CF) have improved survival, reducing high levels of treatment burden remains a priority issue for many people with cystic fibrosis (pwCF). However, economic evaluations of novel interventions may fail to capture their impact on treatment burden due to a lack of suitable outcome measures. This study aimed to estimate health state utilities (HSUs) for changes in treatment burden associated with different CF treatments. Research Question: What value do pwCF place on changes in treatment burden associated with IV antibiotic treatment of pulmonary exacerbations, use of inhaled medicines, and physiotherapy? Study Design and Methods: Adults attending a specialist CF center were invited to participate in a web-based time trade-off interview. Participants valued their own health and five health state vignettes describing varying levels of intensity of physiotherapy, use of inhaled medicines, and IV antibiotic treatment. HSUs for additional instances of each treatment type were estimated using mixed effect linear regression models. Results: Fifty one pwCF completed the interview (median age, 30 years; range, 19-66); 53% were female; mean FEV Interpretation: In this study, increasing treatment burden was associated with decreasing HSU values. The utility decrements associated with treatment burden changes suggest meaningful differences in health-related quality of life for pwCF. These findings align with existing literature on the impact of treatment burden on health-related quality of life, and highlight the importance of considering treatment burden in economic evaluations of interventions in CF.

Indexed as

cystic fibrosishealth-related quality of lifehealth state utilitypatient and public involvementtime trade-offtreatment burden

Identifiers

PMID42548570
PMCPMC13419222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.